Health and Healthcare

Merck : MRK

All Merck Articles

1067 Articles

Chris Lange | Oct 29, 2019 at 10:20 AM EDT

Is This the Turnaround Pfizer and Merck Shareholders Have Been Waiting For?

Shares of Merck and Pfizer both got boosts after they reported their most recent quarterly results before the opening bell…

Chris Lange | Oct 28, 2019 at 1:25 PM EDT

Merck and Pfizer Earnings: What to Expect

Merck and Pfizer are set to report their most recent quarterly results before the opening bell tomorrow. Pfizer is one…

Chris Lange | Oct 27, 2019 at 6:50 AM EDT

Apple, Chevron, Exxon, Pfizer and More Dow Earnings Coming This Week

Six of the 30 Dow Jones industrial average components are scheduled to report their latest quarterly reports this week.

Chris Lange | Oct 25, 2019 at 9:59 AM EDT

Short Sellers Can’t Make Up Their Minds on Big Pharma

The October 15 short interest data have been compared with the previous figures, and short interest moves in these selected…

Jon C. Ogg | Oct 19, 2019 at 6:45 AM EDT

How Biotech and Big Pharma Have Upside Heading Into Earnings

Credit Suisse and Merrill Lynch made calls in the biotech and pharmaceutical space last week, ahead of coming earnings reports.

Jon C. Ogg | Oct 17, 2019 at 9:15 AM EDT

Top Analyst Upgrades and Downgrades: Abbott Labs, CSX, IBM, Netflix, Occidental, Whiting, Amgen, Gilead, Merck, Pfizer and More

Thursday's top analyst upgrades, downgrades and initiations included Abbott Laboratories, CSX, IBM, Netflix, Occidental Petroleum, Whiting Petroleum, Amgen, Gilead Sciences,…

Chris Lange | Oct 10, 2019 at 9:40 AM EDT

Big Pharma Sees Rising Tide in Short Interest

The September 30 short interest data have been compared with the previous figures, and short interest in most of these…

Chris Lange | Oct 2, 2019 at 10:30 AM EDT

FDA Accepts for Review the Newest Treatment for C Diff

Merck has just announced that the FDA has accepted a couple new drug applications for review, including for a treatment…

Lee Jackson | Sep 27, 2019 at 10:45 AM EDT

Why Dividend-Paying Large-Cap Pharmaceuticals Could Shine in Q4

These four top large-cap pharmaceutical stocks for investors to consider all pay solid dividends and look like very solid fourth-quarter…

Chris Lange | Sep 25, 2019 at 9:20 AM EDT

Short Sellers Grow More Selective in Big Pharma

The September 13 short interest data have been compared with the previous figures, and short interest moves in these selected…

Lee Jackson | Sep 25, 2019 at 6:20 AM EDT

4 Conservative Merrill Lynch US 1 Stock Picks That Pay Reliable Dividends

These four outstanding ideas from the US 1 team at Merrill Lynch are decidedly more conservative than most of the…

Chris Lange | Sep 18, 2019 at 9:55 AM EDT

Will This Ebola Vaccine Be the Next Big Thing?

NewLink Genetics shares jumped on Wednesday after the firm announced that the FDA has accepted Merck’s Biologics License Application and…

Jon C. Ogg | Sep 13, 2019 at 7:11 AM EDT

As ESG Investing Expands, the Theme’s Top Stocks Come Into Focus

As, when and if ESG themes continue to gain in popularity, imagine what could happen to some of the top-ranked…

Chris Lange | Sep 12, 2019 at 8:35 AM EDT

Short Sellers Can’t Make Up Their Minds on Big Pharma

The August 30 short interest data have been compared with the previous figures, and short interest in most of these…

Chris Lange | Aug 27, 2019 at 8:35 AM EDT

Big Pharma Sees a Rising Tide in Short Interest

The August 15 short interest data have been compared with the previous figures, and short interest in most of these…

1 … 13 14 15 16 17 … 72

Merck : MRK

All Merck Articles

Is This the Turnaround Pfizer and Merck Shareholders Have Been Waiting For?

Merck and Pfizer Earnings: What to Expect

Apple, Chevron, Exxon, Pfizer and More Dow Earnings Coming This Week

Short Sellers Can’t Make Up Their Minds on Big Pharma

How Biotech and Big Pharma Have Upside Heading Into Earnings

Top Analyst Upgrades and Downgrades: Abbott Labs, CSX, IBM, Netflix, Occidental, Whiting, Amgen, Gilead, Merck, Pfizer and More

Big Pharma Sees Rising Tide in Short Interest

FDA Accepts for Review the Newest Treatment for C Diff

Why Dividend-Paying Large-Cap Pharmaceuticals Could Shine in Q4

Short Sellers Grow More Selective in Big Pharma

4 Conservative Merrill Lynch US 1 Stock Picks That Pay Reliable Dividends

Will This Ebola Vaccine Be the Next Big Thing?

As ESG Investing Expands, the Theme’s Top Stocks Come Into Focus

Short Sellers Can’t Make Up Their Minds on Big Pharma

Big Pharma Sees a Rising Tide in Short Interest

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy’s 25% Savings Rule Actually Starts at 15%

A 71-Year-Old's $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy's 25% Savings Rule Actually Starts at 15%

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Merck : MRK

All Merck Articles

Is This the Turnaround Pfizer and Merck Shareholders Have Been Waiting For?

Merck and Pfizer Earnings: What to Expect

Apple, Chevron, Exxon, Pfizer and More Dow Earnings Coming This Week

Short Sellers Can’t Make Up Their Minds on Big Pharma

How Biotech and Big Pharma Have Upside Heading Into Earnings

Top Analyst Upgrades and Downgrades: Abbott Labs, CSX, IBM, Netflix, Occidental, Whiting, Amgen, Gilead, Merck, Pfizer and More

Big Pharma Sees Rising Tide in Short Interest

FDA Accepts for Review the Newest Treatment for C Diff

Why Dividend-Paying Large-Cap Pharmaceuticals Could Shine in Q4

Short Sellers Grow More Selective in Big Pharma

4 Conservative Merrill Lynch US 1 Stock Picks That Pay Reliable Dividends

Will This Ebola Vaccine Be the Next Big Thing?

As ESG Investing Expands, the Theme’s Top Stocks Come Into Focus

Short Sellers Can’t Make Up Their Minds on Big Pharma

Big Pharma Sees a Rising Tide in Short Interest

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy’s 25% Savings Rule Actually Starts at 15%

Featured Reads

A 71-Year-Old's $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy's 25% Savings Rule Actually Starts at 15%